TheranosticTrials.org

Clinical Trial · NCT00832598

[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors

Overview

The purpose of this study is to help us understand gliomas, one type of brain tumor. This research protocol makes pictures of gliomas. We will take pictures of the glioma before and after treatment. The pictures are made with a positron emission tomography (PET) scanner. PET scans use radioactive markers to "see" cancer cells. We plan to use two different radioactive markers, \[18F\]FACBC and \[18F\]FLT, to "see" if the glioma responds to the treatment being recommended by the doctor. We are investigating whether one or both of these types of PET scans can help us to better understand gliomas and their response to treatment. We expect these pictures will give us information the your tumor and may help us to understand why the treatment that the patient is receiving is affecting the tumor the way that it is. We also hope to collect information about the amount of radioactivity exposure. We will measure radioactivity exposure to the tumor, brain and other organs.

Sponsor

Memorial Sloan Kettering Cancer Center

Phase

N/A

Contacts

Ronald Blasberg, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT00832598

Drug / Compound

FLT

Isotope(s):
Target(s):
  • cytosolic thymidine kinase 1
Ligand Class: Small Molecules

FACBC

Isotope(s):
Target(s):
  • Amino Acid Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Patients planning to start anti-AKT and/or anti-VEGF directed therapies .
  • Patients with gliomas
  • Patients with measurable disease on MRI or CT neuroimaging.
  • Registered patient at MSKCC.

Exclusion

  • Patient cannot tolerate lying still for a 60 minute session in the PET tomograph.
  • Patient is incontinent of urine or stool (which would make them unable to tolerate lying still for 60 minutes).